Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Rini, BI; Pal, SK; Escudier, BJ; Atkins, MB; Hutson, TE; Porta, C; Verzoni, E; Needle, MN; McDermott, DF

Rini, BI (corresponding author), Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.

LANCET ONCOLOGY, 2020; 21 (1): 95

Abstract

Background Treatment for renal cell carcinoma has been revolutionised by inhibitors of VEGF receptor. Previous studies have suggested that treatment w......

Full Text Link